Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD)

Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing their quarterly 13F filings. One of the most fertile grounds for large abnormal returns is hedge funds’ most popular small-cap picks, which are not so widely followed and often trade at a discount to their intrinsic value. In this article we will check out hedge fund activity in another small-cap stock: Audentes Therapeutics, Inc. (NASDAQ:BOLD).

Is Audentes Therapeutics, Inc. (NASDAQ:BOLD) ready to rally soon? Money managers are getting more bullish. The number of long hedge fund bets inched up by 7 recently. Our calculations also showed that bold isn’t among the 30 most popular stocks among hedge funds.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the market by 32 percentage points since May 2014 through March 12, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that’ll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 27.5% through March 12, 2019. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

Samuel Isaly Orbimed Advisors

Let’s go over the key hedge fund action surrounding Audentes Therapeutics, Inc. (NASDAQ:BOLD).

Hedge fund activity in Audentes Therapeutics, Inc. (NASDAQ:BOLD)

At the end of the fourth quarter, a total of 24 of the hedge funds tracked by Insider Monkey were long this stock, a change of 41% from one quarter earlier. Below, you can check out the change in hedge fund sentiment towards BOLD over the last 14 quarters. With the smart money’s sentiment swirling, there exists a few noteworthy hedge fund managers who were increasing their stakes meaningfully (or already accumulated large positions).

No of Hedge Funds with BOLD Positions

Among these funds, Partner Fund Management held the most valuable stake in Audentes Therapeutics, Inc. (NASDAQ:BOLD), which was worth $64.4 million at the end of the fourth quarter. On the second spot was Redmile Group which amassed $49.1 million worth of shares. Moreover, OrbiMed Advisors, Great Point Partners, and Citadel Investment Group were also bullish on Audentes Therapeutics, Inc. (NASDAQ:BOLD), allocating a large percentage of their portfolios to this stock.

With a general bullishness amongst the heavyweights, key hedge funds were breaking ground themselves. Great Point Partners, managed by Jeffrey Jay and David Kroin, assembled the biggest position in Audentes Therapeutics, Inc. (NASDAQ:BOLD). Great Point Partners had $35.3 million invested in the company at the end of the quarter. Israel Englander’s Millennium Management also made a $12.6 million investment in the stock during the quarter. The other funds with brand new BOLD positions are Steve Cohen’s Point72 Asset Management, Ken Greenberg and David Kim’s Ghost Tree Capital, and Jacob Doft’s Highline Capital Management.

Let’s now review hedge fund activity in other stocks similar to Audentes Therapeutics, Inc. (NASDAQ:BOLD). These stocks are Intrexon Corp (NASDAQ:XON), C&J Energy Services, Inc (NYSE:CJ), NCI Building Systems, Inc. (NYSE:NCS), and Coeur Mining, Inc. (NYSE:CDE). This group of stocks’ market values match BOLD’s market value.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
XON 10 29347 1
CJ 25 254818 0
NCS 20 74692 -8
CDE 13 44363 0
Average 17 100805 -1.75

View table here if you experience formatting issues.

As you can see these stocks had an average of 17 hedge funds with bullish positions and the average amount invested in these stocks was $101 million. That figure was $350 million in BOLD’s case. C&J Energy Services, Inc (NYSE:CJ) is the most popular stock in this table. On the other hand Intrexon Corp (NASDAQ:XON) is the least popular one with only 10 bullish hedge fund positions. Audentes Therapeutics, Inc. (NASDAQ:BOLD) is not the most popular stock in this group but hedge fund interest is still above average. Our calculations showed that top 15 most popular stocks) among hedge funds returned 24.2% through April 22nd and outperformed the S&P 500 ETF (SPY) by more than 7 percentage points. Hedge funds were also right about betting on BOLD as the stock returned 85.4% and outperformed the market by an even larger margin. Hedge funds were rewarded for their relative bullishness.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.